ERBB2 and neoplasm: The biological and clinical roles of HER2 activation have been well investigated in the pathogenesis of several malignancies [58,59] and it has been associated with aggressive tumor behavior, poor prognosis, and resistance to chemotherapy as well as with successful anti-HER2 targeted therapies, i.e., having both negative prognostic, as well as positive predictive value [60,61,62,63,64,65,66].